Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1115-1124

  Saiko, Philipp ^a   Graser, Geraldine ^a   Giessrigl, Benedikt ^a   Steinmann, Marie Thérèse ^a   Schuster, Heike ^a   Lackner, Andreas ^a   Grusch, Michael ^a   Krupitza, Georg ^a   Jaeger, Walter ^b   Somepalli, Venkateswarlu ^c   Golakoti, Trimurtulu ^c   Fritzer Szekeres, Monika ^a   Szekeres, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Laila IMPEX   (India)

Author keywords

AsPC 1 cells; BxPC 3 cells; Digalloylresveratrol; Pancreatic cancer; Ribonucleotide reductase

Indexed keywords

ASCORBIC ACID; ATM PROTEIN; CHECKPOINT KINASE 2; DIGALLOYLRESVERATROL; GALLIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHENOL DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; RESVERATROL; RIBONUCLEOTIDE REDUCTASE; TOCOPHEROL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT;

ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CELL CYCLE; CELL LINE, TUMOR; CYTIDINE; DNA; FREE RADICAL SCAVENGERS; GALLIC ACID; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PICRATES; RIBONUCLEOTIDE REDUCTASES; STILBENES;

EID: 84884814088     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0009-x     Document Type: Article

References (54)

1. Almhanna K, Philip PA (2011) Defining new paradigms for the treatment of pancreatic cancer. Curr Treat Options Oncol 12:111-125
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
3. Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339:1523-1526
4. Richard JL (1987) [Coronary risk factors. The French paradox]. Arch Mal Coeur Vaiss 80 Spec No:17-21
5. Appeldoorn CC, Bonnefoy A, Lutters BC, Daenens K, van Berkel TJ, Hoylaerts MF, Biessen EA (2005) Gallic acid antagonizes P-selectin-mediated platelet-leukocyte interactions: implications for the French paradox. Circulation 111:106-112
6. Salucci M, Stivala LA, Maiani G, Bugianesi R, Vannini V (2002) Flavonoids uptake and their effect on cell cycle of human colon adenocarcinoma cells (Caco2). Br J Cancer 86:1645-1651
7. Horvath Z, Saiko P, Illmer C, Madlener S, Hoechtl T, Bauer W, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T (2005) Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol 33:329-335
8. Saiko P, Szakmary A, Jaeger W, Szekeres T (2008) Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 658:68-94
9. Kawada M, Ohno Y, Ri Y, Ikoma T, Yuugetu H, Asai T, Watanabe M, Yasuda N, Akao S, Takemura G, Minatoguchi S, Gotoh K, Fujiwara H, Fukuda K (2001) Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice. Anti Cancer Drugs 12:847-852
10. Madlener S, Illmer C, Horvath Z, Saiko P, Losert A, Herbacek I, Grusch M, Elford HL, Krupitza G, Bernhaus A, Fritzer-Szekeres M, Szekeres T (2007) Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. Cancer Lett 245:156-162
11. Shao J, Zhou B, Chu B, Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6:409-431
12. Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ (2005) Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem 12:1283-1294
13. Takeda E, Weber G (1981) Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci 28:1007-1014
14. Smith BD, Karp JE (2003) Ribonucleotide reductase: an old target with new potential. Leuk Res 27:1075-1076
15. Nocentini G (1996) Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit Rev Oncol Hematol 22:89-126
16. Holland KP, Elford HL, Bracchi V, Annis CG, Schuster SM, Chakrabarti D (1998) Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives. Antimicrob Agents Chemother 42:2456
17. Noble S, Goa KL (1997) Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54:447-472
18. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F (2005) Role of gemcitabine in cancer therapy. Futur Oncol 1:7-17
19. Kolberg M, Strand KR, Graff P, Andersson KK (2004) Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta 1699:1-34
20. Bernhaus A, Fritzer-Szekeres M, Grusch M, Saiko P, Krupitza G, Venkateswarlu S, Trimurtulu G, Jaeger W, Szekeres T (2009) Digalloylresveratrol, a new phenolic acid derivative induces apoptosis and cell cycle arrest in human HT-29 colon cancer cells. Cancer Lett 274:299-304
21. Madlener S, Saiko P, Vonach C, Viola K, Huttary N, Stark N, Popescu R, Gridling M, Vo NT, Herbacek I, Davidovits A, Giessrigl B, Venkateswarlu S, Geleff S, Jager W, Grusch M, Kerjaschki D, Mikulits W, Golakoti T, Fritzer-Szekeres M, Szekeres T, Krupitza G (2010) Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro. Br J Cancer 102:1361-1370
22. Garrett C, Santi DV (1979) A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem 99:268-273
23. Saiko P, Ozsvar-Kozma M, Bernhaus A, Jaschke M, Graser G, Lackner A, Grusch M, Horvath Z, Madlener S, Krupitza G, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T (2007) N-hydroxy-N′-(3,4,5- trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosylcytosine. Int J Oncol 31:1261-1266
24. Szekeres T, Gharehbaghi K, Fritzer M, Woody M, Srivastava A, van't Riet B, Jayaram HN, Elford HL (1994) Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother Pharmacol 34:63-66
25. Saiko P, Graser G, Giessrigl B, Lackner A, Grusch M, Krupitza G, Basu A, Sinha BN, Jayaprakash V, Jaeger W, Fritzer-Szekeres M, Szekeres T (2011) A novel N-hydroxy-N′-Aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C). Biochem Pharmacol 81:50-59
26. Grusch M, Polgar D, Gfatter S, Leuhuber K, Huettenbrenner S, Leisser C, Fuhrmann G, Kassie F, Steinkellner H, Smid K, Peters GJ, Jayaram HN, Klepal W, Szekeres T, Knasmuller S, Krupitza G (2002) Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ 9:169-178
27. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R (1995) In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 21:1465-1468
28. Grusch M, Fritzer-Szekeres M, Fuhrmann G, Rosenberger G, Luxbacher C, Elford HL, Smid K, Peters GJ, Szekeres T, Krupitza G (2001) Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. Exp Hematol 29:623-632
29. Hoshino J, Park EJ, Kondratyuk TP, Marler L, Pezzuto JM, van Breemen RB, Mo S, Li Y, Cushman M (2010) Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 53:5033-5043
30. Guo Y, Xu X, Qi W, Xie C, Wang G, Zhang A, Ge Y (2012) Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines. Mol Med Rep 5:734-738
31. Bernhaus A, Ozsvar-Kozma M, Saiko P, Jaschke M, Lackner A, Grusch M, Horvath Z, Madlener S, Krupitza G, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T (2009) Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Investig New Drugs 27:393-401
32. Horvath Z, Murias M, Saiko P, Erker T, Handler N, Madlener S, Jaeger W, Grusch M, Fritzer-Szekeres M, Krupitza G, Szekeres T (2006) Cytotoxic and biochemical effects of 3,3′,4,4′,5,5′-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Exp Hematol 34:1377-1384
33. Gandhi V, Estey E, Plunkett W (1994) Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol 370:119-124
34. Robinson BW, Im MM, Ljungman M, Praz F, Shewach DS (2003) Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 63:6935-6941
35. Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nat Geosci 432:316-323
36. Chimploy K, Diaz GD, Li Q, Carter O, Dashwood WM, Mathews CK, Williams DE, Bailey GS, Dashwood RH (2009) E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin. Int J Cancer 125:2086-2094
37. Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429
38. Zhu KQ, Zhang SJ (2003) Involvement of ATM/ATR-p38 MAPK cascade in MNNG induced G1-S arrest. World J Gastroenterol 9:2073-2077
39. Ray D, Kiyokawa H (2008) CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res 68:1251-1253
40. Gao G, Peng M, Zhu L, Wei Y, Wu X (2009) Human papillomavirus 16 variant E7 gene induces transformation of NIH 3T3 cells via up-regulation of cdc25A and cyclin A. Int J Gynecol Cancer 19:494-499
41. Madlener S, Rosner M, Krieger S, Giessrigl B, Gridling M, Vo TP, Leisser C, Lackner A, Raab I, Grusch M, Hengstschlager M, Dolznig H, Krupitza G (2009) Short 42 degrees C heat shock induces phosphorylation and degradation of Cdc25A which depends on p38MAPK, Chk2 and 14.3.3. Hum Mol Genet 18:1990-2000
42. Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M, Ikeda Y (2003) Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 15:719-727
43. Lin KL, Su JC, Chien CM, Tseng CH, Chen YL, Chang LS, Lin SR (2010) Naphtho[1,2-b]furan-4,5-dione induces apoptosis and S-phase arrest of MDA-MB-231 cells through JNK and ERK signaling activation. Toxicol In Vitro 24:61-70
44. Johnson GL, Lapadat R (2002) Mitogen-Activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298:1911-1912
45. Cui J, Sun R, Yu Y, Gou S, Zhao G, Wang C (2010) Antiproliferative effect of resveratrol in pancreatic cancer cells. Phytother Res 24:1637-1644
46. Franke TF, Kaplan DR, Cantley LC (1997) PI3K: downstream AKTion blocks apoptosis. Cell 88:435-437
47. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541-6551
48. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137
49. Bozulic L, Hemmings BA (2009) PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 21:256-261
50. Bozulic L, Surucu B, Hynx D, Hemmings BA (2008) PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30:203-213
51. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ (2003) Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89:2110-2115
52. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29:4688-4695
53. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9:1956-1967
54. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O (1998) Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 421:277-279